Aurobindo Pharma has secured final U.S. FDA approval for its generic Beclomethasone Dipropionate HFA inhalation aerosol, marking a major expansion into complex respiratory therapies.

  • Aurobindo Pharma received final FDA approval for Beclomethasone Dipropionate HFA Inhalation Aerosol (40 mcg and 80 mcg).
  • The product is a generic equivalent to Teva's QVAR Inhalation Aerosol.
  • Manufacturing will take place at Aurolife Pharma’s facility in Raleigh, North Carolina.
  • The estimated U.S. market for this product is approximately $301 million.

In a significant regulatory victory, Aurobindo Pharma has announced that it has received final approval from the U.S. Food and Drug Administration (U.S. FDA) to manufacture and market its generic Beclomethasone Dipropionate HFA Inhalation Aerosol in both 40 mcg and 80 mcg strengths.

This product serves as a generic equivalent to QVAR Inhalation Aerosol, which is marketed by Teva Branded Pharmaceutical Products R&D LLC. This milestone is particularly noteworthy as it represents Aurobindo’s first foray into metered-dose inhalers (MDI), signaling a strategic shift into the highly specialized field of complex respiratory therapies.

Read Also:First Export Vessel Departs Vizhinjam International Seaport for Spain

Strategic Expansion into Respiratory Care

The approval allows Aurobindo to compete in the maintenance treatment market for asthma. By moving beyond traditional oral solids into complex inhalation therapies, the company aims to create a new wave of differentiated growth within the competitive United States pharmaceutical landscape.

Production of the approved inhaler will be managed by the company's subsidiary, Aurolife Pharma, at its manufacturing plant located in Raleigh, North Carolina. The company anticipates the commercial launch of the product in the upcoming quarters.

Why This Matters

BozokMedia analysis shows that this move is a calculated attempt to capture higher-margin segments of the generic market. According to data from IQVIA, the U.S. market for the approved product and newer versions of its reference product was estimated at $301 million for the 12-month period ending July 2026, presenting a substantial revenue opportunity for Aurobindo.

Transitioning from simple generics to complex inhalation devices is a hallmark of a maturing pharmaceutical giant seeking long-term value.
Did You Know?: Metered-dose inhalers (MDIs) are designed to deliver a specific, controlled amount of medication to the lungs with every puff.

Frequently Asked Questions

1. What is the purpose of the approved Beclomethasone Dipropionate HFA?
It is indicated for the maintenance treatment of asthma symptoms.

2. Where will this inhaler be manufactured?
It will be produced at the Aurolife Pharma facility in Raleigh, North Carolina.